ClinicalTrials.gg
RecruitingNCT07288879DALY II JapanUpdated Jan 8, 2026

DALY II Japan/MB-CART2019.1 for DLBCL

A Phase 2 interventional study of MB-CART2019.1 in DLBCL - Diffuse Large B Cell Lymphoma and CAR T Cell Therapy, sponsored by Miltenyi Biomedicine GmbH. Recruiting at 5 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Miltenyi Biomedicine GmbH · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

DALY II Japan is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy.

Read the detailed description

A prospective, single arm, open label, multi-center, phase II study of autologous T cells engineered against both CD19 and CD20 antigens for subjects with relapsed or refractory DLBCL after receiving at least two lines of therapy. The investigational agent is the MB-CART2019.1 cells. After successful screening, subjects will undergo leukapheresis to collect product for manufacturing. In preparation for the fresh product infusion, subjects will undergo a lymphodepleting regimen with cyclophosphamide and fludarabine. Cell infusion will be administered intravenously at a dose of 2.5 x 10\^6 CAR+ cells/kg body weight. Subjects will be followed for up to 2 years, for efficacy and safety outcomes as well as health-related quality of life (HRQoL). Additional long-term follow-up will be conducted for participants under a separate long-term follow-up protocol.

02

Conditions studied

  • DLBCL - Diffuse Large B Cell Lymphoma
  • CAR T Cell Therapy

Keywords

  • CAR T Cell therapy
  • DLBCL
03

In context

Lead sponsor

Miltenyi Biomedicine GmbH is the lead sponsor of 20 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed DLBCL or associated subtype, defined by WHO 2016 classification:

    • DLBCL not otherwise specified (NOS)
    • High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
    • High-grade B-cell lymphoma, NOS
    • Primary mediastinal (thymic) large B-cell lymphoma
    • Transformed lymphoma (e.g. transformed follicular or marginal zone lymphoma, follicular lymphoma Grade 3B)
  2. disease after 2 or more including rituximab and anthracycline and either having failed stem cell transplant (ASCT), or being ineligible for or not consenting to ASCT 2.1 Chemotherapy-refractory disease is defined as one of the following:

    • No response to last line of therapy:

      • Progressive disease (PD) as best response to most recent therapy regimen
      • Stable disease (SD) as best response to most recent therapy with duration no longer than 6 months from last dose of therapy OR
    • Relapsed or persistent disease after prior ASCT for lymphoma

      • Disease progression or relapse less than or equal to 24 months of ASCT
      • If salvage therapy is given post-ASCT, the individual must have had no response to or relapsed after the last line of therapy 2.2 Disease relapse in subjects without prior ASCT is defined as relapse of disease in ≤ 12 months after the last dose of most recent therapy regimen 2.3 Ineligible for ASCT is defined as meeting one of the following criteria:
    • Chemotherapy-refractory disease after salvage therapy
    • Disease progression or relapse ≤ 12 months after salvage therapy
    • Intolerance to salvage therapy

    In addition, all subjects must have:

  3. Age ≥18 years
  4. (ECOG) performance status that is either 0 or 1 at screening. ECOG performance status of 2 at screen is allowed if the decrease in performance status is due to DLBCL
  5. according to Lugano 2014 criteria for assessing fluorodeoxyglucose-positron emission tomography (FDG-PET)/computer tomography (CT) in lymphoma (Cheson et al, 2014)
  6. CD19 or CD20 antigen expression on tumor is not required after the most recent chemoimmunotherapy; however, 6.1 Subject must have at least 20 unstained slides of tissue available prior to MB-CART2019.1 infusion 6.2 If is not available, subject must be willing to undergo attempted repeat biopsy
  7. No clinical suspicion of central nervous system (CNS) lymphoma
  8. If the subject has history of CNS disease, then he/she must 8.1. Have no signs or symptoms of CNS disease 8.2. Have no active disease on magnetic resonance imaging (MRI) 8.3. Have no large cell lymphoma present in cerebral spinal fluid (CSF) on cytospin preparation and flow cytometry, regardless of the number of white blood cells (WBCs)
  9. If the subject has history of cerebral vascular accident (CVA) 9.1. The CVA event must be greater than 12 months prior to leukapheresis 9.2. Any neurological deficits must be stable
  10. An estimated by Cockcroft-Gault Equation () > 60mL/min
  11. Cardiac (EF) ≥ 45% as determined by an echocardiogram (ECHO)
  12. Resting O2 saturation >90% on room air
  13. Serum (ALT) / aspartate aminotransferase (AST) \<5 times the (ULN) for age
  14. Total \<1.5 mg/dl, except in individuals with Gilbert's syndrome
  15. (ANC) > 1000/μL
  16. Absolute lymphocyte count > 100/μL
  17. count > 50,000/μL
  18. Estimated of more than 3 months other than primary disease
  19. Subjects of childbearing or child fathering potential must be willing to practice from the time of enrollment on this study until the follow-up period of the study

Exclusion criteria

Exclusion Criteria:

  1. Primary CNS lymphoma
  2. Richter's transformed DLBCL arising from chronic lymphocytic leukemia (CLL)
  3. Unable to give
  4. Known history of infection with (HIV) or active (HBsAg positive), unless confirmed to be polymerase chain reaction (PCR) negative; antiviral prophylaxis is required as recommended in the Japanese guidelines for Hepatitis B treatment if HBsAg negative and anti-HBc positive
  5. Known history of infection with virus (anti-HCV positive) unless viral load is undetectable per quantitative PCR and/or nucleic acid testing
  6. Known history of active seizure or presence of seizure activities or on active anti-seizure medications within the prior 12 months
  7. Known history of CVA within prior 12 months
  8. Known history or presence of CNS disease, such as multiple sclerosis, optic neuritis or other immunologic or inflammatory disease
  9. Presence of active CNS disorder that, in the judgment of the investigator, may impair the ability to evaluate neurotoxicity
  10. Active systemic fungal, viral or bacterial infection
  11. Pregnant or breast-feeding woman
  12. Previous or concurrent with the following exceptions:

    • Adequately treated basal cell or squamous cell carcinoma (adequate wound healing is required prior to study entry)
    • In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 2 years prior to the study
    • Adequately treated breast or prostate carcinoma on hormonal therapies such as Lupron or tamoxifen and in clinical remission of ≥ 2 years
    • A primary malignancy which has been completely resected / treated with curative intent and in complete remission of ≥ 2 years
  13. History of non-neurologic autoimmune disease (e.g. Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) requiring systemic or systemic disease modifying agents within the last 2 years
  14. Medical condition requiring prolonged use of systemic equivalent to Prednisone >10 mg/day
  15. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other cardiac disease within 6 months of enrollment
  16. Concurrent radiotherapy (allow up to time of leukapheresis)
  17. Baseline dementia that would interfere with therapy or monitoring, determined using Immune Effector Cell-Associated Encephalopathy (ICE) Assessment at baseline. (Appendix 6, Section 13.6)
  18. History of severe immediate reaction to any of the agents used in this study
  19. Refusal to participate in additional lentiviral gene therapy LTFU protocol
  20. Prior CAR T cell therapy for any indication
  21. Prior stem cell transplant for any indication.
  22. Prior bispecific antibodies for cancer therapy
  23. Prior T cell receptor-engineered T cell therapy
  24. Prior anti CD 19 immunotherapy
  25. Hypersensitivity against any drug including MB-CART2019.1 (and the constituents used in the production, ingredients/impurities, including bovine and rodent-derived components), that is scheduled or likely to be given during trial participation, e.g. as part of the mandatory preparative chemotherapy or rescue medication/salvage therapies for treatment related toxicities.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (estimated)

Study arms

  • Experimental
    MB-CART2019.1 in DLBCL

    MB-CART2019.1 Treatment

    Biological: MB-CART2019.1

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Objective Response Rate (ORR) (complete response rate \[CRR\] + partial response rate \[PRR\]) using Lugano 2014 Criteria (Cheson et al, 2014) at one month with independent central review

    Time frame: 1 month

Secondary outcomes

  1. Complete Response Rate

    Complete response rate using Lugano 2014 Criteria (Cheson et al, 2014) at 6 months.

    Time frame: 6 months

  2. Duration of response

    Duration of response (DOR)

    Time frame: up to 2 years

  3. Objective Response Rate

    ORR using Lugano 2014 criteria (Cheson et al, 2014) at 6 months.

    Time frame: 6 months

  4. Best Overall Response

    Best overall response (BOR)

    Time frame: 2 years

  5. Progression Free Survival

    Progression Free Survival

    Time frame: up to 2 years

  6. Overall Survival

    Overall Survival

    Time frame: up to 2 years

  7. Type, frequency, and severity of adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESI)

    Type, frequency, and severity of adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESI)

    Time frame: up to 2 years

  8. Incidence of anti-MB-CART2019.1 antibodies

    Incidence of anti-MB-CART2019.1 antibodies

    Time frame: up to 2 years

  9. Persistence of MB-CART2019.1

    Persistence of MB-CART2019.1

    Time frame: up to 2 years

  10. Cytokine levels

    Measure and correlate the types and level of cytokines in subjects following MB-CART2019.1 infusion with severity of CRS, ICANS and efficacy.

    Time frame: up to 2 years

  11. CD19 and CD20 antigen expression

    Correlate the changes in tumor CD19 and CD20 antigen expression with disease progression and relapse

    Time frame: up to 2 years

  12. Quality of Life /Patient-Reported Outcome assessments: EQ-5D-5L Health-Related Quality of Life Index Score

    Measured using the EQ-5D-5L instrument. The index score reflects health utility (range -0.281 to 1.000), where higher scores indicate better self-reported health status.

    Time frame: Baseline, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24

  13. Quality of Life /Patient-Reported Outcome assessments: Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Total Score

    The FACT-Lym is a patient-reported outcome instrument designed to assess health-related quality of life in patients with lymphoma. The total score is derived from the FACT-General core questionnaire (physical, social/family, emotional, and functional well-being) and a lymphoma-specific subscale. Higher scores indicate better health-related quality of life.

    Time frame: Baseline, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24

07

Study locations

2 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Jan 2027, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Dec 17, 2025
StartActual
Dec 11, 2025
Primary completionEst.
Jan 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07288879
Lead sponsor
Miltenyi Biomedicine GmbH
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Dec 11, 2025
Primary completion
Jan 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jan 8, 2026

Study contacts

Clinical Trial Manager
Contact
clinicaltrials.gov@miltenyi.com
+4922048306820

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zamtocabtagene autoleucel

Start the discussion